ReviewJournal of thrombosis and haemostasis : JTH2019
Red blood cells: the forgotten player in hemostasis and thrombosis.
Review in Journal of thrombosis and haemostasis : JTH, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 205 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
205 citing papers in PubMed, 2 syntheses or guidelines pooled it, 453 citations in OpenAlex.
- Management of antithrombotic therapies in kidney transplantation candidates and recipients: an ERBP clinical practice document by the DESCaRTES Working Group of ERA and the EKITA Committee of ESOT.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Guideline
- Interaction of von Willebrand factor with blood cells in flow models: a systematic review.Blood advances · 2022Pooled it
- Biomaterial-mediated blood clot formation: a key to unlocking osteogenic synergy for bone regeneration.Bone research · 2026Review
- Mechanisms of Piezo1-Mediated Mechanotransduction in Thrombotic Diseases.International journal of molecular sciences · 2026Review
- Tasisulam-induced suicidal death of human erythrocytes.Biochemistry and biophysics reports · 2026Article
- Multivalent Bi-Specific Nanoerythrosomes: A Two-Birds-One-Stone Approach to Combine Homologous and Active Targeting for Effective Thrombolysis.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Systemic Ammonia Toxicity: An Underestimated Driver of Cerebral Energy Crisis in Hepatic Encephalopathy.International journal of molecular sciences · 2026Review
- Curcumin's Protective Effects Against HMolecules (Basel, Switzerland) · 2026Review
- Philadelphia-negative myeloproliferative neoplasms and acquired von Willebrand syndrome: only pertinent at diagnosis?Research and practice in thrombosis and haemostasis · 2026Article
- Potential Role of Polyphenols in Platelet Aggregation and Blood Coagulation.Journal of cardiovascular development and disease · 2026Review
- Splenic erythrophagocytosis is regulated by ALX/FPR2 signaling.Haematologica · 2026Article
- Article
- Mechanobiology of cancer-associated thrombosis: from molecular mechanisms to therapeutic innovation.Journal of nanobiotechnology · 2026Review
- Catechol functionalized polyguluronate enriched sodium alginate wetspun fibers with immobilized platelet lysate for diabetic wound healing.RSC advances · 2026Article
- Toward improved thrombolysis in ischemic stroke: targeting nonfibrin components.Research and practice in thrombosis and haemostasis · 2026Review
- Hemocompatibility of Carbosilane Dendrimers as a Therapeutic siRNA Delivery System across Blood-Brain Barrier.ACS applied materials & interfaces · 2026Article
- RTX-family toxin EhxA drives morphological remodeling and thrombogenesis in RBCs during enterohemorrhagicScience advances · 2026Article
- Red Blood Cells in Normal and Pathological States: Redox Reactions of Hemoglobin.Molecules (Basel, Switzerland) · 2026Review
- Therapeutic potential of vitamin D in improving antioxidant defense and blood rheology in a rat model of experimental diabetes mellitus.Open medicine (Warsaw, Poland) · 2026Article
- Construction and validation of the risk assessment scale for deep vein thrombosis in high altitude plateau areas.Frontiers in medicine · 2026Article
145 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
New evidence has stirred up a long-standing but undeservedly forgotten interest in the role of erythrocytes, or red blood cells (RBCs), in blood clotting and its disorders. This review summarizes the most recent research that describes the involvement of RBCs in hemostasis and thrombosis. There are both quantitative and qualitative changes in RBCs that affect bleeding and thrombosis, as well as interactions of RBCs with cellular and molecular components of the hemostatic system. The changes in RBCs that affect hemostasis and thrombosis include RBC counts or hematocrit (modulating blood rheology through viscosity) and qualitative changes, such as deformability, aggregation, expression of adhesive proteins and phosphatidylserine, release of extracellular microvesicles, and hemolysis. The pathogenic mechanisms implicated in thrombotic and hemorrhagic risk include variable adherence of RBCs to the vessel wall, which depends on the functional state of RBCs and/or endothelium, modulation of platelet reactivity and platelet margination, alterations of fibrin structure and reduced susceptibility to fibrinolysis, modulation of nitric oxide availability, and the levels of von Willebrand factor and factor VIII in blood related to the ABO blood group system. RBCs are involved in platelet-driven contraction of clots and thrombi that results in formation of a tightly packed array of polyhedral erythrocytes, or polyhedrocytes, which comprises a nearly impermeable barrier that is important for hemostasis and wound healing. The revisited notion of the importance of RBCs is largely based on clinical and experimental associations between RBCs and thrombosis or bleeding, implying that RBCs are a prospective therapeutic target in hemostatic and thrombotic disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.